Medivation (MDVN +4.3%) continues to move higher today on the back of Friday's early approval of...

|By:, SA News Editor

Medivation (MDVN +4.3%) continues to move higher today on the back of Friday's early approval of its prostate cancer drug Xtandi by the FDA. Wedbush says that ultimately Xtandi will surpass Zytiga in sales and the pre-chemotherapy data for the drug is going to make it the market leader.